Okay.

So, um, when we started pulling data and, you know, the, the first data point that we wanted to look at was one year.

Are, are patients having this, this difference in their, you know, functioning of their valve at one year? And we didn't see that.

And I started talking with, you know, Dr. Turek and with, with Joe and, and really thinking, and I think there were, there were two critical things that happened.

There, there was that finding that we weren't seeing the difference that we thought we were going to see.

Um, and the second thing was we in the lab started doing xenotransplant studies in the context of partial heart transplantation, and that was where I learned about the bioburden of alpha-gal antibodies in the average human being.

Every person makes anti-Gal IgA, IgG, and IgM antibodies.

[laughs]